Company Filing History:
4 out of 1,209 
1 out of 3,923 
Years Active: 2017-2020
Title: Yubao Wang: Innovator in Cancer Treatment
Introduction
Yubao Wang is a prominent inventor based in Newton, MA (US), known for his significant contributions to cancer treatment through innovative pharmaceutical compounds. With a total of 4 patents, Wang has focused on developing small molecule inhibitors that target specific kinases involved in cancer progression.
Latest Patents
Wang's latest patents include groundbreaking work on salicylate inhibitors of maternal embryonic leucine zipper kinase (MELK). These small molecule inhibitors are designed to treat cancer and other conditions associated with aberrant MELK expression. The patent details the structure of these compounds and their pharmaceutical compositions, which include a pharmaceutically acceptable carrier. Additionally, Wang has developed tricyclic kinase inhibitors of MELK, which also aim to address cancers linked to over-expression of MELK.
Career Highlights
Throughout his career, Yubao Wang has worked with esteemed organizations such as Dana-Farber Cancer Institute Inc. and Novartis AG. His work in these institutions has allowed him to advance his research and contribute to the field of oncology significantly.
Collaborations
Wang has collaborated with notable colleagues, including Jean Zhao and Nathanael Schiander Gray, enhancing the impact of his research through teamwork and shared expertise.
Conclusion
Yubao Wang's innovative work in developing MELK inhibitors showcases his dedication to advancing cancer treatment. His contributions through patents and collaborations highlight the importance of research in the fight against cancer.